<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1159">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146063</url>
  </required_header>
  <id_info>
    <org_study_id>SYSEC-KY-KS-2021-187</org_study_id>
    <nct_id>NCT05146063</nct_id>
  </id_info>
  <brief_title>LNK in Polycystic Ovary Syndrome With Insulin Resistance</brief_title>
  <official_title>LNK Participates in Insulin Resistance in Polycystic Ovary Syndrome by Regulating Adipose Glucose Transport</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin resistance (IR) is an important pathological feature of polycystic ovary syndrome&#xD;
      (PCOS), with an incidence rate of up to 85%, which seriously affects the patient's fertility,&#xD;
      quality of life, and offspring health, but the mechanism is unknown. The adaptor protein LNK&#xD;
      is closely related to metabolic diseases. Our exome sequencing has found that the mutation&#xD;
      rate of LNK gene in patients with PCOS and IR is high. Studies have found that LNK can affect&#xD;
      adipose inflammation and impair glucose tolerance. Whether LNK is related to fat metabolism&#xD;
      is worth further study. Our previous research found that: LNK expression was significantly&#xD;
      increased in adipose tissue of patients with PCOS and IR. Knockout of LNK in PCOS IR model&#xD;
      mice can reduce serum triglycerides, free fatty acids, high-sensitivity C-reactive protein&#xD;
      levels and reduce fatty liver occurrence, which indicates that LNK has a mitigating effect on&#xD;
      IR. Mechanism studies have shown that LNK knockout can upregulate the glucose transporter&#xD;
      Glut4, also LNK and insulin receptor substrate IRS-1 can form protein complexes. Based on the&#xD;
      above research basis, we propose the following scientific hypothesis: LNK in adipose tissue&#xD;
      can regulate insulin signaling pathway by binding to IRS-1, downregulate Glut4, and&#xD;
      participate in PCOS IR occurrence. This project intends to clarify the specific mechanism by&#xD;
      which LNK regulates glucose transport and participate in IR in combination with clinical&#xD;
      specimens, animal models and cell experiments, and provide scientific basis for LNK as a&#xD;
      potential therapeutic target for PCOS IR.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>mRNA expression levels of LNK</measure>
    <time_frame>2 years</time_frame>
    <description>The expression level of LNK mRNA in the subcutaneous adipose tissue of the PCOS patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>protein expression levels of LNK</measure>
    <time_frame>2 years</time_frame>
    <description>The expression level of LNK protein in the subcutaneous adipose tissue of the PCOS patients</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Polycystic Ovarian Syndrome</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Polycystic ovary syndrome patients with insulin resistance</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Polycystic ovary syndrome patients without insulin resistance</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Take the patient's subcutaneous fat tissue to detect the expression of LNK</intervention_name>
    <description>Take the patient's subcutaneous fat tissue to detect the mRNA and protein expression levels of LNK by RT-qPCR and western blot.</description>
    <arm_group_label>Polycystic ovary syndrome patients with insulin resistance</arm_group_label>
    <arm_group_label>Polycystic ovary syndrome patients without insulin resistance</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with polycystic ovary syndrome who met the 2003 Rotterdam criteria were divided&#xD;
        into insulin resistance group and non-insulin resistance group&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with polycystic ovary syndrome who meet the 2003 Rotterdam criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Do not meet the diagnostic criteria for polycystic ovary syndrome&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Zhang</last_name>
    <role>Study Director</role>
    <affiliation>Sun Yat-sen Memorial Hospital, Sun Yat-sen Univers</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Zhang</last_name>
    <phone>+862081332120</phone>
    <email>sys_iit@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaozhu Zhong, Doctor</last_name>
      <phone>02081332233</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 11, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

